Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks
Highlights Triple Blockade Strategy And Differentiated TIGIT Molecule
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
